medigraphic.com
Academia Mexicana de Neurología, A.C.

2018, Number 1

<< Back Next >>

Rev Mex Neuroci 2018; 19 (1)

Tauopathy associated to anti-IgLON5 antibodies

García-Nuño DK, Ramírez VLHJ, Soto EJA, Zúñiga RC

Language: Spanish
References: 24
Page: 94-103
PDF size: 429.62 Kb.


ABSTRACT

Antibodies against IgLON5 have been found in subjects who develop sleep disorders with gait instability, abnormal ocular movements, bulbar symptoms, movement disorders, dysautonomia and cognitive decline. These patients share the HLA DRB1*1001 and DqB1*0501 alleles and hystopathological features of neurodegeneration with neuronal hyperphosphorylated Tau deposits mostly in hypothalamus and brainstem without inflammatory changes. Even though antibody-associated neurological diseases usually improve after immunotherapy, this entity shows poor response and a fatal prognosis, representing a mixture of immunological and neurodegenerative mechanisms.


REFERENCES

  1. Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: A case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13(6):575–86.

  2. Simabukuro MM, Sabater L, Adoni T, Cury RG, Haddad MS, Moreira CH, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol NeuroInflammation. 2015;2(4):1–2.

  3. Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol. 2015;22(8):1151–61.

  4. Gelpi E, Höftberger R, Graus F, Ling H, Holton JL, Dawson T, et al. Neuropathological criteria of anti- IgLON5-related tauopathy. Acta Neuropathol. 2016;132(4):531–43.

  5. Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation. 2016;13(1):226.

  6. Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88(18):1736–43.

  7. Archelos JJ, Hartung HP. Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci. 2000;23(7):317–27.

  8. Gold M, Pul R, Bach JP, Stangel M, Dodel R. Pathogenic and physiological autoantibodies in the central nervous system. Immunol Rev. 2012;248(1):68–86.

  9. Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al. IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol - Neuroimmunol Neuroinflammation. 2017;4(5):1–8.

  10. Dale RC, Ramanathan S. Cell surface antibody-associated neurodegeneration: The case of anti- IgLON5 antibodies. Neurology. 2017;88(18):1688–90.

  11. Balint B, Bhatia KP. Stiff person syndrome and other immune-mediated movement disorders – new insights. Curr Opin Neurol. 2016;29(4):1.

  12. Hashimoto T, Maekawa S, Miyata S. IgLON cell adhesion molecules regulate synaptogenesis in hippocampal neurons. Cell Biochem Funct. 2008;27:496–8.

  13. Tan, R.P., Leshchyns’ka, I, Sytnyk, V. Glucosylphosphatidilinositol-Anchored Immunoglobulin Superfamily Cell Adhesion Molecules and Their Role in Neuronal Development and Synapse Regulation. Front Mol Neurosci. 2017;10:378.

  14. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Parsons TD, et al. Cellular and Synaptic Mechanisms of Anti-NMDAR Encephalitis. J Neurosci. 2010;30(17):5866–75.

  15. Cagnin A, Mariotto S, Fiorini M, Gaule M, Bonetto N, Tagliapietra M, et al. Microglial and Neuronal TDP-43 Pathology in Anti-IgLON5-Related Tauopathy. J Alzheimer’s Dis. 2017;59:1–8.

  16. Högl B, Heidbreder A, Santamaria J, Graus F, Poewe W. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet. 2015;385(9977):1590.

  17. Schröder JB, Melzer N, Ruck T, Heidbreder A, Kleffner I, Dittrich R, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol NeuroInflammation. 2017;4(1):1–6.

  18. Montojo MT, Piren V, Benkhadra F, Codreanu A, Wirt G, Kerschen P, et al. Mimicking Progressive Supranuclear Palsy And Causing Tako‐Tsubo Syndrome: A Case Report On IgLON5-Encephalopathy. Mov Disord. 2015;30(suppl 1):710.

  19. Brüggemann N, Wandinger KP, Gaig C, Sprenger A, Junghanns K, Helmchen C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord. 2016;31(5):762–4.

  20. Bahtz R, Teegen B, Borowski K, Probst C, Brücker I-M, Fechner K, et al. Autoantibodies against IgLON5: Two new cases. J Neuroimmunol. 2014;275(1–2):8.

  21. Salmon DP, Filoteo JV. Neuropsychology of cortical versus subcortical dementia syndromes. Semin Neurol. 2007;27(1):7–21.

  22. Haitao R, Yingmai Y, Yan H, Fei H, Xia L, Honglin H, et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol. 2016;300:9–10.

  23. Lang K, Prüss H. Frequencies of neuronal autoantibodies in healthy controls. Neurol - Neuroimmunol Neuroinflammation. 2017;4(5):1–8.

  24. Zhang W, Niu N, Cui R. Serial 18 F-FDG PET/CT Findings in a Patient With IgLON5 Encephalopathy. Clin Nucl Med. 2016;41(10):787–8.




2020     |     www.medigraphic.com